Cytogen Inc
217330
Company Profile
Business description
Cytogen Inc is a Korea based company engaged in developing HD Microporous chip using microfluidics and nanotechnology and it captures viable CTCS (circulating tumor cells) from cancer patients blood. The firm operates in two business areas including Liquid Biopsy Applications and Liquid Biopsy Platforms. Its services and products include: cancer drug development and monitoring, companion diagnostics, clinical research, CLIA-certified services, preclinical xenograft models, and liquid biopsy equipment.
Contact
128, Beobwon-ro
8th floor, Building A
Munjeong-dong, Munjeong SK V1
Songpa-gu
Seoul05854
KORT: +82 269251070
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
45
Stocks News & Analysis
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
Microsoft’s earnings report is expected to touch on AI adoption and monetization.
stocks
World’s largest miner overvalued after solid quarter
The ongoing war is likely to keep commodity prices even more volatile than usual until it is resolved.
stocks
Hidden value in an expensive ASX
How investors can uncover value beyond the index heavyweights.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,024.20 | 27.20 | -0.30% |
| CAC 40 | 8,163.02 | 6.59 | 0.08% |
| DAX 40 | 24,070.83 | 124.07 | -0.51% |
| Dow JONES (US) | 49,490.03 | 340.65 | 0.69% |
| FTSE 100 | 10,387.81 | 88.65 | -0.85% |
| HKSE | 25,915.20 | 248.04 | -0.95% |
| NASDAQ | 24,657.57 | 397.60 | 1.64% |
| Nikkei 225 | 59,140.23 | 445.63 | -0.75% |
| NZX 50 Index | 12,884.93 | 60.67 | -0.47% |
| S&P 500 | 7,137.90 | 73.89 | 1.05% |
| S&P/ASX 200 | 8,793.40 | 26.10 | -0.30% |
| SSE Composite Index | 4,093.25 | 13.01 | -0.32% |